-
Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells.
Toxicological sciences : an official journal of the Society of Toxicology 20180801
-
The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
Toxicology in vitro : an international journal published in association with BIBRA 20170801
-
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
The Lancet. Neurology 20160201
-
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Brain research 20130225
-
The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.
Toxicologic pathology 20120801
-
Drugs for treating Parkinson disease.
Nursing 20120701
-
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
JAMA 20120606
-
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
European journal of neurology 20120601
-
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Journal of clinical psychopharmacology 20120601
-
Microbial β-glycosylation of entacapone by Cunninghamella echinulata ATCC 9245.
Journal of bioscience and bioengineering 20120501
-
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
European journal of clinical pharmacology 20120301
-
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Expert review of neurotherapeutics 20120201
-
Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
Clinical neuropharmacology 20120101
-
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
Clinical neuropharmacology 20120101
-
Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.
Bioorganic & medicinal chemistry 20111215
-
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
European journal of neurology 20111201
-
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology 20111201
-
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
The International journal of neuroscience 20111101
-
Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.
Drug metabolism and disposition: the biological fate of chemicals 20111101
-
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Hiroshima journal of medical sciences 20110901
-
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Parkinsonism & related disorders 20110801
-
Species independence in brain tissue binding using brain homogenates.
Drug metabolism and disposition: the biological fate of chemicals 20110701
-
Entacapone promotes cAMP-dependent colonic Cl(-) secretion in rats.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20110701
-
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Naunyn-Schmiedeberg's archives of pharmacology 20110601
-
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
Drug metabolism and disposition: the biological fate of chemicals 20110401
-
In-line reaction monitoring of entacapone synthesis by Raman spectroscopy and multivariate analysis.
Journal of pharmaceutical and biomedical analysis 20110325
-
Development of characterization methods for entacapone in a pharmaceutical bulk.
Journal of pharmaceutical and biomedical analysis 20110325
-
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
European journal of neurology 20110301
-
Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Journal of pharmaceutical and biomedical analysis 20110220
-
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
Annals of neurology 20110201
-
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Journal of clinical pharmacology 20110101
-
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
CNS drugs 20110101
-
Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
Clinical neuropharmacology 20110101
-
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Annals of neurology 20110101
-
Identification and categorization of liver toxicity markers induced by a related pair of drugs.
International journal of molecular sciences 20110101
-
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
CNS neuroscience & therapeutics 20101201
-
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals 20101201
-
Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.
Parkinsonism & related disorders 20101201
-
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
International journal of clinical pharmacology and therapeutics 20101101
-
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Nature reviews. Neurology 20101101
-
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20101001
-
Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957.
Nuclear medicine and biology 20101001
-
LC determination of entacapone in tablets: in vitro dissolution studies.
Journal of chromatographic science 20101001
-
Entacapone: prostate cancer?
Prescrire international 20101001
-
Isolated delusional syndrome in Parkinson's Disease.
Parkinsonism & related disorders 20100901
-
Entacapone.
Expert opinion on drug metabolism & toxicology 20100801
-
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Current medical research and opinion 20100701
-
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Annals of neurology 20100701
-
Continuous dopaminergic therapy in Parkinson disease: time to stride back?
Annals of neurology 20100701
-
Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.
The Journal of biological chemistry 20100514
-
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.
Journal of medicinal chemistry 20100422
-
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Journal of neural transmission (Vienna, Austria : 1996) 20100301
-
The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.
Movement disorders : official journal of the Movement Disorder Society 20100215
-
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Brain research 20100114
-
Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
Toxicological sciences : an official journal of the Society of Toxicology 20100101
-
Mirtazapine-associated urinary retention.
The Journal of neuropsychiatry and clinical neurosciences 20100101
-
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Clinical drug investigation 20100101
-
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
International review of neurobiology 20100101
-
LC/MS/MS study for identification of entacapone degradation product obtained by photodegradation kinetics.
Journal of AOAC International 20100101
-
Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.
Movement disorders : official journal of the Movement Disorder Society 20091215
-
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
European journal of neurology 20091201
-
Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
Movement disorders : official journal of the Movement Disorder Society 20091115
-
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Journal of neural transmission (Vienna, Austria : 1996) 20091001
-
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Movement disorders : official journal of the Movement Disorder Society 20090715
-
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Parkinsonism & related disorders 20090701
-
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.
PLoS computational biology 20090701
-
Levodopa/carbidopa/entacapone in Parkinson's disease.
Expert review of neurotherapeutics 20090701
-
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
European journal of clinical pharmacology 20090501
-
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20090415
-
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20090315
-
Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215
-
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.
Neurological research 20090201
-
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
European journal of neurology 20090201
-
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Movement disorders : official journal of the Movement Disorder Society 20090115
-
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
European neurology 20090101
-
The liver toxicity biomarker study: phase I design and preliminary results.
Toxicologic pathology 20090101
-
Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation.
Journal of AOAC International 20090101
-
Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.
Clinical drug investigation 20090101
-
Establishing the probable mechanism of L-DOPA in Alzheimer's disease management.
Acta poloniae pharmaceutica 20090101
-
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.
Journal of the neurological sciences 20081215
-
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Neurobiology of disease 20081201
-
Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
Current medical research and opinion 20081101
-
[Treatment of Parkinson's disease at present and in the future].
Rinsho shinkeigaku = Clinical neurology 20081101
-
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20080730
-
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
European journal of neurology 20080701
-
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 20080601
-
Homocysteine in restless legs syndrome.
Sleep medicine 20080501
-
The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.
Psychopharmacology 20080401
-
Long-term retention rate of entacapone in the treatment of Parkinson's disease.
European journal of neurology 20080401
-
On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.
Neuropharmacology 20080401
-
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
European journal of neurology 20080301
-
[Isolated pulmonary hypertension and pergolide].
Revue neurologique 20080301
-
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Clinical neuropharmacology 20080101
-
[Entocapone-related lymphocytic colitis].
Gastroenterologie clinique et biologique 20080101
-
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
CNS neuroscience & therapeutics 20080101
-
Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Clinical neuropharmacology 20080101
-
The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.
Clinical neuropharmacology 20080101
-
Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.
Parkinsonism & related disorders 20071201
-
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Experimental neurology 20071201
-
Parkinson disease: an incremental challenge.
South Dakota medicine : the journal of the South Dakota State Medical Association 20071201
-
Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function.
Journal of pharmaceutical sciences 20071101
-
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
The Annals of pharmacotherapy 20071101
-
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
Movement disorders : official journal of the Movement Disorder Society 20070815
-
[Neuromuscular disorders due to adverse effects of antiparkinson agents].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810
-
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.
Movement disorders : official journal of the Movement Disorder Society 20070730
-
Entacapone improves complex movement performance in patients with Parkinson's disease.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20070501
-
Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.
Chemico-biological interactions 20070501
-
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?
Neurology 20070424
-
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Neurology 20070424
-
Current pharmacotherapeutic treatment options in Parkinson's disease.
Disease-a-month : DM 20070401
-
Does the preferred orientation of crystallites in tablets affect the intrinsic dissolution?
Journal of pharmaceutical and biomedical analysis 20070312
-
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
European journal of neurology 20070301
-
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20070101
-
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.
Movement disorders : official journal of the Movement Disorder Society 20070101
-
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 20070101
-
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
European neurology 20070101
-
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
Clinical neuropharmacology 20070101
-
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
Movement disorders : official journal of the Movement Disorder Society 20061201
-
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 20061001
-
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Acta neurologica Scandinavica 20060901
-
Long-term care of Parkinson's disease. Strategies for managing 'wearing off' symptom re-emergence and dyskinesias.
Geriatrics 20060901
-
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Journal of the American Medical Directors Association 20060901
-
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Expert opinion on pharmacotherapy 20060701
-
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Neurology 20060627
-
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Movement disorders : official journal of the Movement Disorder Society 20060501
-
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Movement disorders : official journal of the Movement Disorder Society 20060301
-
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Acta neurologica Scandinavica 20060101
-
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Journal of motor behavior 20060101
-
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Clinical neuropharmacology 20060101
-
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
Clinical neuropharmacology 20060101
-
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
Clinical neuropharmacology 20060101
-
Synthesis and biological evaluation of a novel series of 'ortho-nitrated' inhibitors of catechol-O-methyltransferase.
Journal of medicinal chemistry 20051215
-
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.
Neurology 20051213
-
Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
Journal of mass spectrometry : JMS 20051201
-
High-performance liquid chromatography method for the quantification of entacapone in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050905
-
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Journal of neural transmission (Vienna, Austria : 1996) 20050901
-
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
Parkinsonism & related disorders 20050901
-
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.
Drug metabolism and disposition: the biological fate of chemicals 20050701
-
Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases.
Analytical biochemistry 20050601
-
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Parkinsonism & related disorders 20050601
-
Entacapone in the treatment of Parkinson's disease.
The Lancet. Neurology 20050601
-
Prediction of genotoxicity of chemical compounds by statistical learning methods.
Chemical research in toxicology 20050601
-
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Neurologia (Barcelona, Spain) 20050501
-
The effect of entacapone on homocysteine levels in Parkinson disease.
Neurology 20050426
-
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Pharmacology & therapeutics 20050401
-
The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050401
-
Novel pharmacological strategies for motor complications in Parkinson's disease.
Expert opinion on investigational drugs 20050401
-
'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease.
Neurology 20050308
-
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Movement disorders : official journal of the Movement Disorder Society 20050301
-
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Experimental neurology 20050301
-
Rasagiline for motor complications in Parkinson's disease.
Lancet (London, England) 20050301
-
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet (London, England) 20050301
-
Improving quality of life in early Parkinson's.
Health news (Waltham, Mass.) 20050201
-
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Movement disorders : official journal of the Movement Disorder Society 20050101
-
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Acta neurologica Scandinavica 20050101
-
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society 20050101
-
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Clinical neuropharmacology 20050101
-
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
European neurology 20050101
-
Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase.
Journal of medicinal chemistry 20041202
-
Assessment of catechol induction and glucuronidation in rat liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 20041201
-
Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.
Naunyn-Schmiedeberg's archives of pharmacology 20041101
-
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
The Cochrane database of systematic reviews 20041018
-
Clinical advantages of COMT inhibition with entacapone - a review.
Journal of neural transmission (Vienna, Austria : 1996) 20041001
-
Extraneuronal enzymatic degradation of myocardial interstitial norepinephrine in the ischemic region.
Cardiovascular research 20041001
-
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Archives of neurology 20041001
-
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Movement disorders : official journal of the Movement Disorder Society 20040901
-
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
European journal of neurology 20040901
-
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Journal of neural transmission (Vienna, Austria : 1996) 20040801
-
Role of entacapone in later Parkinson's disease not yet established.
Journal of neurology, neurosurgery, and psychiatry 20040701
-
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Expert review of neurotherapeutics 20040701
-
Bullous skin eruption associated with entacapone.
International journal of dermatology 20040601
-
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20040601
-
Stalevo for Parkinson's disease.
The Medical letter on drugs and therapeutics 20040510
-
In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle.
Autonomic neuroscience : basic & clinical 20040430
-
[Treatment in Parkinson disease].
Orvosi hetilap 20040411
-
An active and water-soluble truncation mutant of the human UDP-glucuronosyltransferase 1A9.
Molecular pharmacology 20040401
-
Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Neuropharmacology 20040301
-
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Journal of neural transmission (Vienna, Austria : 1996) 20040201
-
The role of COMT inhibition in the treatment of Parkinson's disease.
Neurology 20040113
-
Safety and tolerability of COMT inhibitors.
Neurology 20040113
-
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Neurology 20040113
-
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
Neurology 20040113
-
Levodopa/carbidopa/entacapone (Stalevo).
Neurology 20040113
-
The value of post-marketing medication surveys in Parkinson's disease.
Current medical research and opinion 20040101
-
Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
Current medical research and opinion 20040101
-
[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20040101
-
Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease.
Clinical neuropharmacology 20040101
-
Entacapone protects from angiotensin II-induced inflammation and renal injury.
Journal of hypertension 20031201
-
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20031001
-
Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20031001
-
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Progress in neuro-psychopharmacology & biological psychiatry 20030901
-
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Journal of neurology, neurosurgery, and psychiatry 20030801
-
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 20030801
-
An artist's view of drug-induced hallucinosis.
Movement disorders : official journal of the Movement Disorder Society 20030701
-
The economic evaluation of pharmacotherapies for Parkinson's disease.
Parkinsonism & related disorders 20030601
-
Absorption rate limit considerations for oral phosphate prodrugs.
Pharmaceutical research 20030601
-
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
MMW Fortschritte der Medizin 20030526
-
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Movement disorders : official journal of the Movement Disorder Society 20030501
-
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Expert opinion on drug safety 20030501
-
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
European journal of neurology 20030301
-
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Journal of neural transmission (Vienna, Austria : 1996) 20030301
-
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
The Journal of pharmacology and experimental therapeutics 20030201
-
Excessive daytime sleepiness and 'sleep attacks' induced by entacapone.
Fundamental & clinical pharmacology 20030201
-
Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.
Fundamental & clinical pharmacology 20030201
-
Position of COMT inhibition in the treatment of Parkinson's disease.
Advances in neurology 20030101
-
Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Parkinsonism & related disorders 20030101
-
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Drugs in R&D 20030101
-
Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.
Journal of neural transmission (Vienna, Austria : 1996) 20021101
-
Entacapone-induced hepatotoxicity and hepatic dysfunction.
Movement disorders : official journal of the Movement Disorder Society 20021101
-
Effects of entacapone and tolcapone on mitochondrial membrane potential.
European journal of pharmacology 20021018
-
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
British journal of clinical pharmacology 20021001
-
[The usefulness of dopaminergic drugs in traumatic brain injury].
Revista de neurologia 20020801
-
[Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome].
Der Nervenarzt 20020801
-
Catechol-o-methyltransferase and blood pressure in humans.
Circulation 20020723
-
Comparison of electrospray, atmospheric pressure chemical ionization, and atmospheric pressure photoionization in the identification of apomorphine, dobutamine, and entacapone phase II metabolites in biological samples.
Analytical chemistry 20020715
-
Entacapone in the management of Parkinson's disease.
Expert opinion on pharmacotherapy 20020701
-
Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20020701
-
Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Pharmacology & toxicology 20020601
-
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
Parkinsonism & related disorders 20020601
-
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
British journal of clinical pharmacology 20020501
-
Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
Journal of neural transmission (Vienna, Austria : 1996) 20020501
-
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Acta neurologica Scandinavica 20020401
-
Design and synthesis of a novel L-dopa-entacapone codrug.
Journal of medicinal chemistry 20020314
-
Entacapone in restless legs syndrome.
Movement disorders : official journal of the Movement Disorder Society 20020301
-
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.
Neurology 20020226
-
Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.
Journal of medicinal chemistry 20020131
-
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Journal of neural transmission (Vienna, Austria : 1996) 20020101
-
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
PharmacoEconomics 20020101
-
COMT inhibitors: management of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 20020101
-
Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
The Journal of pharmacy and pharmacology 20011101
-
Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats.
Toxicological sciences : an official journal of the Society of Toxicology 20010901
-
Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 20010815
-
L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.
Psychopharmacology 20010801
-
Current advances in Parkinson's disease.
Trends in neurosciences 20010701
-
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Clinical therapeutics 20010601
-
[Parkinson disease. Value of COMT inhibitors is verified].
MMW Fortschritte der Medizin 20010503
-
D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
Kidney international 20010501
-
Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
Synapse (New York, N.Y.) 20010401
-
[Parkinson's disease].
Presse medicale (Paris, France : 1983) 20010303
-
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Neurologia (Barcelona, Spain) 20010201
-
Possible applications for dopaminergic agents following traumatic brain injury: part 2.
The Journal of head trauma rehabilitation 20010201
-
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
European neurology 20010101
-
Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
Journal of neural transmission (Vienna, Austria : 1996) 20010101
-
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Clinical neuropharmacology 20010101
-
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
European journal of clinical pharmacology 20010101
-
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Journal of neural transmission (Vienna, Austria : 1996) 20010101
-
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
Seminars in neurology 20010101
-
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Clinical neuropharmacology 20010101
-
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
European neurology 20010101
-
Twelve-month safety of entacapone in patients with Parkinson's disease.
European journal of neurology 20010101
-
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
Clinical neuropharmacology 20010101
-
Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20010101
-
COMT inhibition and safety.
Functional neurology 20010101
-
[Dopaminergic agonists in the treatment of Parkinson's disease].
Revue medicale de Bruxelles 20001201
-
Entacapone.
The Annals of pharmacotherapy 20000901
-
Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
Drugs 20000601
-
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
The European journal of neuroscience 20000301
-
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Biochemistry 19950404
-
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
European journal of pharmacology 19950214